Cargando…
Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARD...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589715/ https://www.ncbi.nlm.nih.gov/pubmed/28884313 http://dx.doi.org/10.1186/s13613-017-0311-4 |
_version_ | 1783262388202504192 |
---|---|
author | Orbegozo, Diego Rahmania, Lokmane Irazabal, Marian Mendoza, Manuel Annoni, Filippo De Backer, Daniel Creteur, Jacques Vincent, Jean-Louis |
author_facet | Orbegozo, Diego Rahmania, Lokmane Irazabal, Marian Mendoza, Manuel Annoni, Filippo De Backer, Daniel Creteur, Jacques Vincent, Jean-Louis |
author_sort | Orbegozo, Diego |
collection | PubMed |
description | BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARDS) could help predict risk of death or of prolonged ventilation. METHODS: All patients present in the department of intensive care during a 150-day period were screened for ARDS (using the Berlin definition). Endocan concentrations were measured at the moment of ARDS diagnosis (T0) and the following morning (T1). We compared data from survivors and non-survivors and data from survivors with less than 10 days of ventilator support (good evolution) and those who died or needed more than 10 days of mechanical ventilation (poor evolution). Results are presented as numbers (percentages), mean ± standard deviation or medians (percentile 25–75). RESULTS: Ninety-six consecutive patients were included [median APACHE II score of 21 (17–27) and SOFA score of 9 (6–12), PaO(2)/FiO(2) ratio 155 (113–206)]; 64 (67%) had sepsis and 51 (53%) were receiving norepinephrine. Non-survivors were older (66 ± 15 vs. 59 ± 18 years, p = 0.045) and had higher APACHE II scores [27 (22–30) vs. 20 (15–24), p < 0.001] and blood lactate concentrations at study inclusion [2.1 (1.3–4.0) vs. 1.5 (0.9–2.6) mmol/L, p = 0.024] than survivors, but PaO(2)/FiO(2) ratios [150 (116–207) vs. 158 (110–206), p = 0.95] were similar in the two groups. Endocan concentrations on the day after ARDS diagnosis were significantly higher in patients with poor evolution than in those with good evolution [12.0 (6.8–18.6) vs. 7.2 (5.4–12.5), p < 0.01]. CONCLUSION: Blood endocan concentrations early in the evolution of ARDS may be a useful marker of disease severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0311-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5589715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55897152017-09-27 Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome Orbegozo, Diego Rahmania, Lokmane Irazabal, Marian Mendoza, Manuel Annoni, Filippo De Backer, Daniel Creteur, Jacques Vincent, Jean-Louis Ann Intensive Care Research BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARDS) could help predict risk of death or of prolonged ventilation. METHODS: All patients present in the department of intensive care during a 150-day period were screened for ARDS (using the Berlin definition). Endocan concentrations were measured at the moment of ARDS diagnosis (T0) and the following morning (T1). We compared data from survivors and non-survivors and data from survivors with less than 10 days of ventilator support (good evolution) and those who died or needed more than 10 days of mechanical ventilation (poor evolution). Results are presented as numbers (percentages), mean ± standard deviation or medians (percentile 25–75). RESULTS: Ninety-six consecutive patients were included [median APACHE II score of 21 (17–27) and SOFA score of 9 (6–12), PaO(2)/FiO(2) ratio 155 (113–206)]; 64 (67%) had sepsis and 51 (53%) were receiving norepinephrine. Non-survivors were older (66 ± 15 vs. 59 ± 18 years, p = 0.045) and had higher APACHE II scores [27 (22–30) vs. 20 (15–24), p < 0.001] and blood lactate concentrations at study inclusion [2.1 (1.3–4.0) vs. 1.5 (0.9–2.6) mmol/L, p = 0.024] than survivors, but PaO(2)/FiO(2) ratios [150 (116–207) vs. 158 (110–206), p = 0.95] were similar in the two groups. Endocan concentrations on the day after ARDS diagnosis were significantly higher in patients with poor evolution than in those with good evolution [12.0 (6.8–18.6) vs. 7.2 (5.4–12.5), p < 0.01]. CONCLUSION: Blood endocan concentrations early in the evolution of ARDS may be a useful marker of disease severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0311-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-09-07 /pmc/articles/PMC5589715/ /pubmed/28884313 http://dx.doi.org/10.1186/s13613-017-0311-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Orbegozo, Diego Rahmania, Lokmane Irazabal, Marian Mendoza, Manuel Annoni, Filippo De Backer, Daniel Creteur, Jacques Vincent, Jean-Louis Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title | Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title_full | Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title_fullStr | Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title_full_unstemmed | Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title_short | Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
title_sort | endocan as an early biomarker of severity in patients with acute respiratory distress syndrome |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589715/ https://www.ncbi.nlm.nih.gov/pubmed/28884313 http://dx.doi.org/10.1186/s13613-017-0311-4 |
work_keys_str_mv | AT orbegozodiego endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT rahmanialokmane endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT irazabalmarian endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT mendozamanuel endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT annonifilippo endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT debackerdaniel endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT creteurjacques endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome AT vincentjeanlouis endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome |